Clinical Trials Directory

Trials / Completed

CompletedNCT03455296

Fluid Management Surgical Patients in Intensive Care Unit.

Fluid Management Guided With Lactate Clearance Versus Central Venous Oxygen Saturation Monitoring in Surgical Patients in Intensive Care Unit.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
National Hepatology & Tropical Medicine Research Institute · Other Government
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the efficacy of lactate clearance (LCR) versus central venous oxygen saturation (ScVO2) to guide fluid management for post-operative patients in the intensive care unit (ICU).

Detailed description

Sixty patients will be randomly assigned in a 1:1 manner into two groups; (group A= thirty patients = ScVO2) \& (group B = thirty patients =lactate clearance). Fluid therapy will be initiated in each group with maintenance in the form of crystalloid e.g. Ringer or Ringer acetate (in a dose of 30-35 ml/Kg/day) plus replacement with crystalloid e.g. Ringer, Ringer acetate or saline 0.9%, 500 ml over 10-30 min. that will be administered in boluses \[7\] guided by ScVO2with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively with close regular clinical monitoring/30min., CVP limits 12-16 cmH2O \& mean arterial pressure (MAP) 65-90mmHg. Maintenance fluid without replacement will be initiated alone if ScVO2 or lactate value normalized or are normal from the start. All demographic data will be obtained including the patients' age, sex, body mass index (BMI), associated co-morbidities (diabetes mellitus \&hypertension), Sequential Organ Failure Assessment (SOFA) on admission \& discharge from ICU, duration of surgery, the type of surgery, the amount of blood loss intraoperative, the amount of blood transfused intraoperative, the need\&the amount of blood transfusion postoperative \& will be recorded. Follow-up hemodynamics including the heart rate, mean arterial pressure (MAP), CVP, arterial oxygen saturation (SaO2), urine volume, fluid balance, blood gases (base excess, PH), hypoxic index (PaO2/FIO2 ratio) \& total fluid infused as a baseline then followed as required. Monitoring of either lactate level or ScVO2 on admission followed and recorded at regular intervals during treatment on 0, 2, 6, 12, 24 \& 48hours. Laboratory investigations including the complete blood profile, prothrombin time, liver functions, serum creatinine \& serum electrolytes will be assessed at randomization as a baseline \& then will be recorded as required. Postoperative medical or surgical morbidities will be followed during ICU \& hospital stay e.g. weight gain, impairment of hypoxic index (P/F ratio), pulmonary edema, pleural effusion, need for mechanical ventilation, paralytic ileus, renal impairment\& intra-abdominal bleeding.28-day mortality will be asked for \& followed by calling the telephone number of the patient or one of his/her first-degree relatives.

Conditions

Interventions

TypeNameDescription
OTHERfluid therapy; crystalloidmaintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.

Timeline

Start date
2018-08-01
Primary completion
2020-02-15
Completion
2020-05-15
First posted
2018-03-06
Last updated
2021-03-19

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03455296. Inclusion in this directory is not an endorsement.